| Value | ₹15.07 Cr |
|---|
BSE filing, NSE: FREDUN. Summary written from the filing by ALFA Finder's alert engine.
Fredun Pharmaceuticals Ltd: key numbers
- Share price
- ₹1,469.40
- Market cap
- ₹2,106 Cr
- Revenue (annual)
- ₹635.5 Cr
- Net profit (annual)
- ₹32.62 Cr
- P/E (TTM)
- 48.0×Sector 46.5×
- Promoter holding
- 43.62%-0.95% QoQ
- FII holding
- 0.69%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Fredun Pharmaceuticals Ltd
All →Fredun Pharmaceuticals Convertible Warrants
Fredun Pharmaceuticals allotted 44,000 equity shares to three non-promoter investors on conversion of 14,667 warrants. The conversion follows the 1:2 bonus issue, which adjusted warrant entitlements.
Fredun Pharmaceuticals Other Announcement
Fredun Pharmaceuticals Ltd submitted its quarterly shareholding pattern for the period ending September 30, 2026. The disclosure provides the equity holding structure for shareholders.
Fredun Pharmaceuticals Other Announcement
Fredun Pharmaceuticals filed a compliance certificate under Regulation 74(5) of the SEBI (DP) Regulations, 2018. It confirms the processing of dematerialized shares for the quarter.
Fredun Pharmaceuticals Business Update
Fredun Pharma announces strategic pet-care acquisitions, capacity expansion, and a 100% branded portfolio target by 2029. H1 FY27 business update outlines multi-pillar growth transformation.
- manufacturing infrastructure (Palghar plant)
- 90000 sq. ft.
Fredun Pharmaceuticals Capital Structure Change
Fredun Pharmaceuticals allotted 1,82,400 equity shares upon the conversion of 60,800 warrants. The company received total consideration of ₹7.60 Crore for this warrant conversion.
- Value
- ₹7.60 Cr
Fredun Pharmaceuticals Capital Structure Change
Fredun Pharmaceuticals has allotted 1,82,400 equity shares following the conversion of 60,800 warrants into equity shares, completing the preferential issue conversion process.
Other capital structure change announcements
All →Meesho Capital Structure Change
Meesho approved up to Rs.400 Crore capital infusion into its wholly owned subsidiary, Meesho Payments. Board also approved a new subsidiary and further Kirana Club investments.
- Value
- ₹400.0 Cr
Womancart Capital Structure Change
Womancart Limited submitted its draft letter of offer for a rights issue of up to Rs.1,200 lakhs to eligible shareholders. The issue is pending in-principle approval from NSE Emerge, with the price, ratio and dates still blank.
- Value
- ₹12.00 Cr
Hero MotoCorp Capital Structure Change
Hero MotoCorp's board approved up to ₹300 Crore additional investment in wholly-owned subsidiary HMCL Netherlands B.V., in tranches over two years. Quarterly results were also approved.
- Value
- ₹300.0 Cr
- Execution
- 2 years, in one or more tranches
Great Eastern Shipping Company Capital Structure Change
Great Eastern Shipping bought back 88,877 equity shares on 28 October 2026 at an average of Rs.1,529.71. Total shares bought back under the open-market buyback now stand at 38,48,494.
- Value
- ₹13.60 Cr
Advanced Enzyme Technologies Capital Structure Change
Advanced Enzyme bought back 64,583 shares on 28-10-2026 at an average ₹262.49, totalling 23,56,451 shares to date. Purchases were made via Emkay Global on the open market.
- Value
- ₹1.70 Cr
Blue Chip Tex Industries Capital Structure Change
Counter Cyclical Investments PMS sold 2,986 shares (0.15%) of Blue Chip Tex via open market, reducing its stake from 5.62% to 5.46%. The filing is a non-promoter SAST Reg 29(2) disclosure.